Axonics, Inc. (AXNX)
- Previous Close
67.43 - Open
67.50 - Bid 48.22 x 200
- Ask 86.40 x 200
- Day's Range
67.20 - 67.65 - 52 Week Range
47.59 - 69.68 - Volume
313,796 - Avg. Volume
792,229 - Market Cap (intraday)
3.435B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.31 - Earnings Date Jul 25, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
71.73
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
www.axonics.comRecent News: AXNX
Performance Overview: AXNX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AXNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AXNX
Valuation Measures
Market Cap
3.44B
Enterprise Value
3.13B
Trailing P/E
--
Forward P/E
625.00
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.64
Price/Book (mrq)
5.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.12%
Return on Assets (ttm)
-0.68%
Return on Equity (ttm)
-2.65%
Revenue (ttm)
387.14M
Net Income Avi to Common (ttm)
-15.95M
Diluted EPS (ttm)
-0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
332.81M
Total Debt/Equity (mrq)
5.04%
Levered Free Cash Flow (ttm)
-7.38M
Research Analysis: AXNX
Company Insights: AXNX
AXNX does not have Company Insights